Palvella Therapeutics (DE:PI6)

FRANKFURT:PI6

PI6

Palvella Therapeutics

RESEARCH TOOLSreports

Palvella Therapeutics (PI6) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PI6 Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Palvella

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PI6 Stock 12 Month Forecast

Average Price Target

€199.34

▲(81.22% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Palvella Therapeutics in the last 3 months. The average price target is €199.34 with a high forecast of €231.50 and a low forecast of €179.19. The average price target represents a 81.22% change from the last price of €110.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","70":"€70","124":"€124","178":"€178","232":"€232"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":231.4951758,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€231.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":199.34306805,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€199.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":179.19441386,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€179.19</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,70,124,178,232],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107,116.57655198461538,126.15310396923077,135.72965595384616,145.30620793846154,154.88275992307692,164.45931190769232,174.0358638923077,183.61241587692308,193.18896786153846,202.76551984615384,212.34207183076924,221.91862381538462,{"y":231.4951758,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107,114.10331292692308,121.20662585384615,128.30993878076924,135.4132517076923,142.51656463461538,149.61987756153846,156.72319048846154,163.82650341538462,170.92981634230767,178.03312926923076,185.13644219615384,192.23975512307692,{"y":199.34306805,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107,112.55341645076923,118.10683290153847,123.66024935230769,129.21366580307694,134.76708225384616,140.32049870461537,145.87391515538462,151.42733160615384,156.98074805692306,162.5341645076923,168.08758095846153,173.64099740923075,{"y":179.19441386,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€231.50

Average Price Target€199.34

Lowest Price Target€179.19

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Whitney Ijem

Canaccord Genuity

€65.53→€194.63

Buy

76.93%

Upside

Reiterated

04/02/26

Analysts Offer Insights on Healthcare Companies: Tilray (NASDAQ: TLRY), Immunovant (NASDAQ: IMVT) and Palvella Therapeutics (NASDAQ: PVLA)

Sam Slutsky

LifeSci Capital

€77.17→€190.34

Buy

73.04%

Upside

Reiterated

04/01/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Insight Molecular Diagnostics (NASDAQ: IMDX) and Delcath Systems (NASDAQ: DCTH)

Andrew Fein

H.C. Wainwright

€231.5

Buy

110.45%

Upside

Reiterated

04/01/26

De-Risked SELVA Trial Success and Scalable QTORIN Platform Underpin Buy Rating on Palvella

Graig Suvannavejh

Mizuho Securities

€214.35

Buy

94.86%

Upside

Reiterated

04/01/26

Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), MAIA Biotechnology, Inc. (NYSE MKT: MAIA) and Palvella Therapeutics (NASDAQ: PVLA)

Jeet Mukherjee

BTIG

€184.34

Buy

67.58%

Upside

Reiterated

04/01/26

Palvella Therapeutics (PVLA) Gets a Buy from BTIG

Ritu Baral

TD Cowen

€228.92

Buy

108.11%

Upside

Reiterated

03/31/26

Positive Risk‑Reward on PVLA Driven by Low‑Risk QTORIN Rapamycin NDA and Strong Cash Runway

Trevor Allred

Oppenheimer

€171.48→€180.05

Buy

63.68%

Upside

Reiterated

03/31/26

Palvella Therapeutics price target raised to $210 from $200 at OppenheimerPalvella Therapeutics price target raised to $210 from $200 at Oppenheimer

Geulah Livshits

Chardan Capital

€188.63→€205.77

Buy

87.07%

Upside

Reiterated

03/31/26

Analysts Conflicted on These Healthcare Names: Palvella Therapeutics (NASDAQ: PVLA) and Apellis Pharmaceuticals (NASDAQ: APLS)

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

03/19/26

Analysts Offer Insights on Healthcare Companies: Spectral AI (NASDAQ: MDAI) and Palvella Therapeutics (NASDAQ: PVLA)

Kaveri Pohlman

Clear Street

€171.48→€188.63

Buy

71.48%

Upside

Reiterated

03/02/26

Palvella Therapeutics (PVLA) Receives a Buy from Clear Street

Danielle Brill

Truist Financial

€162.9→€180.05

Buy

63.68%

Upside

Reiterated

02/25/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Annabel Samimy

Stifel Nicolaus

€154.33→€214.35

Buy

94.86%

Upside

Reiterated

02/24/26

Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Warby Parker (WRBY)

Catherine Novack

JonesTrading

€122.61→€179.19

Buy

62.90%

Upside

Reiterated

02/24/26

Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch

Joshua Schimmer

Cantor Fitzgerald

€171.48→€180.05

Buy

63.68%

Upside

Reiterated

12/15/25

Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald

Dev Prasad

Lucid Capital

€104.6→€181.77

Buy

65.24%

Upside

Reiterated

12/15/25

Palvella Therapeutics price target raised to $212 from $122 at Lucid CapitalPalvella Therapeutics price target raised to $212 from $122 at Lucid Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Whitney Ijem

Canaccord Genuity

€65.53→€194.63

Buy

76.93%

Upside

Reiterated

04/02/26

Analysts Offer Insights on Healthcare Companies: Tilray (NASDAQ: TLRY), Immunovant (NASDAQ: IMVT) and Palvella Therapeutics (NASDAQ: PVLA)

Sam Slutsky

LifeSci Capital

€77.17→€190.34

Buy

73.04%

Upside

Reiterated

04/01/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Insight Molecular Diagnostics (NASDAQ: IMDX) and Delcath Systems (NASDAQ: DCTH)

Andrew Fein

H.C. Wainwright

€231.5

Buy

110.45%

Upside

Reiterated

04/01/26

De-Risked SELVA Trial Success and Scalable QTORIN Platform Underpin Buy Rating on Palvella

Graig Suvannavejh

Mizuho Securities

€214.35

Buy

94.86%

Upside

Reiterated

04/01/26

Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), MAIA Biotechnology, Inc. (NYSE MKT: MAIA) and Palvella Therapeutics (NASDAQ: PVLA)

Jeet Mukherjee

BTIG

€184.34

Buy

67.58%

Upside

Reiterated

04/01/26

Palvella Therapeutics (PVLA) Gets a Buy from BTIG

Ritu Baral

TD Cowen

€228.92

Buy

108.11%

Upside

Reiterated

03/31/26

Positive Risk‑Reward on PVLA Driven by Low‑Risk QTORIN Rapamycin NDA and Strong Cash Runway

Trevor Allred

Oppenheimer

€171.48→€180.05

Buy

63.68%

Upside

Reiterated

03/31/26

Palvella Therapeutics price target raised to $210 from $200 at OppenheimerPalvella Therapeutics price target raised to $210 from $200 at Oppenheimer

Geulah Livshits

Chardan Capital

€188.63→€205.77

Buy

87.07%

Upside

Reiterated

03/31/26

Analysts Conflicted on These Healthcare Names: Palvella Therapeutics (NASDAQ: PVLA) and Apellis Pharmaceuticals (NASDAQ: APLS)

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

03/19/26

Analysts Offer Insights on Healthcare Companies: Spectral AI (NASDAQ: MDAI) and Palvella Therapeutics (NASDAQ: PVLA)

Kaveri Pohlman

Clear Street

€171.48→€188.63

Buy

71.48%

Upside

Reiterated

03/02/26

Palvella Therapeutics (PVLA) Receives a Buy from Clear Street

Danielle Brill

Truist Financial

€162.9→€180.05

Buy

63.68%

Upside

Reiterated

02/25/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Annabel Samimy

Stifel Nicolaus

€154.33→€214.35

Buy

94.86%

Upside

Reiterated

02/24/26

Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Warby Parker (WRBY)

Catherine Novack

JonesTrading

€122.61→€179.19

Buy

62.90%

Upside

Reiterated

02/24/26

Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch

Joshua Schimmer

Cantor Fitzgerald

€171.48→€180.05

Buy

63.68%

Upside

Reiterated

12/15/25

Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald

Dev Prasad

Lucid Capital

€104.6→€181.77

Buy

65.24%

Upside

Reiterated

12/15/25

Palvella Therapeutics price target raised to $212 from $122 at Lucid CapitalPalvella Therapeutics price target raised to $212 from $122 at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Palvella Therapeutics

3 Months

xxx

Success Rate

10/11 ratings generated profit

Average Return

+74.17%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 90.91% of your transactions generating a profit, with an average return of +74.17% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

11/11 ratings generated profit

Average Return

+323.05%

reiterated a buy rating 12 days ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +323.05% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+355.36%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +355.36% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PI6 Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PI6 has received 32 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. PI6 average Analyst price target in the past 3 months is 199.34.

Each month's total comprises the sum of three months' worth of ratings.

PI6 Financial Forecast

PI6 Earnings Forecast

The previous quarter’s earnings for PI6 were -€0.92.

PI6 Sales Forecast

The previous quarter’s earnings for PI6 were €0.00.

PI6 Stock Forecast FAQ

What is DE:PI6’s average 12-month price target, according to analysts?

Based on analyst ratings, Palvella Therapeutics’s 12-month average price target is 199.34.

What is DE:PI6’s upside potential, based on the analysts’ average price target?

Palvella Therapeutics has 81.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Palvella Therapeutics a Buy, Sell or Hold?

Palvella Therapeutics has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Palvella Therapeutics’s share price target?

The average share price target for Palvella Therapeutics is 199.34. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €231.50 ,and the lowest forecast is €179.19. The average share price target represents 81.22% Increase from the current price of €110.

What do analysts say about Palvella Therapeutics?

Palvella Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Palvella Therapeutics?

To buy shares of DE:PI6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Palvella Therapeutics (PI6) Stock Forecast & Price Target

PI6 Analyst Ratings

PI6 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Palvella Therapeutics

PI6 Analyst Recommendation Trends

PI6 Financial Forecast

PI6 Earnings Forecast

PI6 Sales Forecast

PI6 Stock Forecast FAQ

Detailed List of Analyst Forecasts